您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > RS 504393
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
RS 504393
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
RS 504393图片
CAS NO:300816-15-3
包装与价格:
包装价格(元)
1 mg电议
5 mg电议
10 mg电议
25 mg电议
50 mg电议
100 mg电议
200 mg电议
500 mg电议
1 mL*10 mM(in DMSO)电议

产品介绍
RS 504393 是一种高度选择性的 CCR2 趋化因子受体拮抗剂,作用于人重组 CCR2 和 CCR1 受体,IC50值分别为 89 nM 和大于 100 μM。

产品描述

RS 504393 is a highly selective CCR2 chemokine receptor antagonist (IC50s: 89 nM and >100 μM for human recombinant CCR2 and CCR1).

体外活性

RS-504393 inhibit MCP-1-stimulated calcium influx into CCR2-CHL cells. The IC50 values are 35 nM [1]. CCR2 antagonist, RS 504393 treatment, suppressed allergen induced β-hexosaminidase release significantly. This inhibitory effect was partially reversed by supplementation of recombinant MCP-1 protein (100 pg/mL) [2].

体内活性

Whereas vehicle-treated mice developed clear signs of acute inflammation, RS 504393-treated mice failed to show clinical signs of immediate hypersensitivity. No effect was observed in naive animals. The degranulation of mast cells was significantly inhibited in RS 504393-treated mice but had no effect on naive mice [2]. Similar to the results obtained from CCR2-deficient mice, the treatment with RS-504393 significantly reduced renal pathology, especially the extensive interstitial fibrosis mediated by a decrease in type I collagen synthesis [3].

激酶实验

Briefly, binding was measured using membranes prepared from two cell lines, THP-1 and CCR2-CHL cells. Each competition assay was composed of cell membranes, 50 pM 125I-MCP, MCP buffer, protease inhibitors, and test compound. Equilibrium was achieved by incubation at 28?°C for 90 min. Membrane-bound 125I-MCP was collected by filtration through GF/B filters presoaked in polyethyleneimine and bovine serum albumin, followed by four rapid washes with approximately 0.5 ml of ice-cold buffer containing 0.5 M NaCl and 10 mM HEPES, pH 7.4. MCP buffer consists of 50 mMHEPES, pH 7.2, 1 mM CaCl2, 5 mMMgCl2, and 0.1% bovine serum albumin. Protease inhibitors include 0.1 mM phenylmethylsulfonyl fluoride, 1 μM leupeptin, and 0.35 mg/ml pepstatin. THP-1 cells are a human monocyte cell line that express both CCR1 and CCR2. CCR2-CHL cells are Chinese hamster lung cells that have been stably transformed with an expression vector bearing the human CCR2b receptor [1].

细胞实验

Briefly, cytosolic calcium influx was measured in CCR2-CHL cells loaded with the fluorescent dye Fura-2-AM. Quantitation of signal intensity used the integrated signal intensity for 82 s after the addition of chemokine and thus has units of M·s. Antagonism by various compounds of calcium influx was measured using an approximate ED50 dose of MCP-1 (3 nM) and an approximate ED25 dose for MCP-3 (5 nM). Chemotaxis was measured over 1 h using THP-1–5X cells in a 96-well Boyden chamber apparatus. Cell migration through the polycarbonate filter was quantified by fluorescent staining using propidium iodide in 0.1% Triton X-100. These assays typically gave stimulated to unstimulated migration of 6-fold, range 4–10-fold, using a maximally effective concentration of MCP-1. Chemotaxis antagonist measurements used 3 nM MCP-1 or RANTES; these concentrations are near the ED95 attractant concentration for MCP-1 and for RANTES as agonists. The data are expressed by normalization to the uninhibited migration caused by the agonist chemokine. The antagonist was present in both chambers of the Boyden apparatus [1].

动物实验

To evaluate the therapeutic effects of MCP-1/CCR2 signaling, either propagermanium (3 or 8 mg/kg orally once a day) or RS-504393 (2 mg/kg orally twice a day) was mandatorily injected into their mouths to wild-type mice from 3 days before ureteral ligation until the day of sacrifice. In addition, to determine the viability for the usage of CCR2 antagonists for the treatment of renal fibrosis, propagermanium (8 mg/kg) was given daily, beginning 4 days after ureter ligation. For pathological examination, both the obstructed and contralateral kidneys were harvested from UUO animals 4, 7, and 14 days after ureteral ligation (n = 5 at each time point). Untreated age-matched male wild-type mice and CCR2-deficient mice were used as normal control (n = 6 for each group). Since propagermanium treatment was started from 3 days before ureteral ligation, mice treated with propagermanium for 3 days at day 0 were used as a negative control (n = 5) [3].

Cas No.

300816-15-3

分子式

C25H27N3O3

分子量

417.509

储存和溶解度

DMSO:10 mg/mL (23.95 mM)
H2O:Insoluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years